141 related articles for article (PubMed ID: 35058147)
21. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
Cengiz M; Ozenirler S
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
[TBL] [Abstract][Full Text] [Related]
22. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population.
Zambrano-Huailla R; Guedes L; Stefano JT; de Souza AAA; Marciano S; Yvamoto E; Michalczuk MT; Vanni DS; Rodriguez H; Carrilho FJ; Alvares-da-Silva MR; Gadano A; Arrese M; Miranda AL; Oliveira CP
Ann Hepatol; 2020; 19(6):622-626. PubMed ID: 32919087
[TBL] [Abstract][Full Text] [Related]
24. Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD.
Welsh JA; Scorletti E; Clough GF; Englyst NA; Byrne CD
J Leukoc Biol; 2018 Sep; 104(3):631-639. PubMed ID: 29603349
[TBL] [Abstract][Full Text] [Related]
25. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
26. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease.
Chhatwal J; Dalgic OO; Chen W; Samur S; Bethea ED; Xiao J; Hur C; Corey KE; Loomba R
JAMA Netw Open; 2022 Sep; 5(9):e2230426. PubMed ID: 36098969
[TBL] [Abstract][Full Text] [Related]
27. Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study.
Huang DQ; Ahlholm N; Luukkonen PK; Porthan K; Amangurbanova M; Madamba E; Bettencourt R; Siddiqi H; Cervantes V; Hernandez C; Lopez SJ; Richards L; Nemes K; Isoniemi H; Yki-Järvinen H; Loomba R
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):81-90.e4. PubMed ID: 37406954
[TBL] [Abstract][Full Text] [Related]
28. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
[TBL] [Abstract][Full Text] [Related]
29. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
[No Abstract] [Full Text] [Related]
30. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
31. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography.
Kim D; Kim WR; Talwalkar JA; Kim HJ; Ehman RL
Radiology; 2013 Aug; 268(2):411-9. PubMed ID: 23564711
[TBL] [Abstract][Full Text] [Related]
32. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.
Pennisi G; Enea M; Romero-Gomez M; Viganò M; Bugianesi E; Wong VW; Fracanzani AL; Sebastiani G; Boursier J; Berzigotti A; Eslam M; Ampuero J; Benmassaoud A; La Mantia C; Mendoza YP; George J; Craxì A; Camma' C; de Ledinghen V; Petta S
Aliment Pharmacol Ther; 2022 Mar; 55(5):604-615. PubMed ID: 34988994
[TBL] [Abstract][Full Text] [Related]
33. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
34. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
Younossi ZM; Stepanova M; Myers RP; Younossi I; Henry L
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):970-977.e1. PubMed ID: 35533993
[TBL] [Abstract][Full Text] [Related]
35. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
Papatheodoridi M; Hiriart JB; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; de Ledinghen V; Pinzani M; Tsochatzis EA
J Hepatol; 2021 May; 74(5):1109-1116. PubMed ID: 33307138
[TBL] [Abstract][Full Text] [Related]
36. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Aguilar Schall R; Jia C; McColgan B; Djedjos CS; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Muir AJ; Afdhal NH; Bosch J; Goodman Z
Hepatology; 2019 Dec; 70(6):1913-1927. PubMed ID: 30993748
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
[TBL] [Abstract][Full Text] [Related]
38. The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease.
Petta S; Tuttolomondo A; Gagliardo C; Zafonte R; Brancatelli G; Cabibi D; Cammà C; Di Marco V; Galvano L; La Tona G; Licata A; Magliozzo F; Maida C; Marchesini G; Merlino G; Midiri M; Parrinello G; Torres D; Pinto A; Craxì A
Medicine (Baltimore); 2016 Apr; 95(16):e3446. PubMed ID: 27100443
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of MRI-derived liver surface nodularity score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease.
Catania R; Furlan A; Smith AD; Behari J; Tublin ME; Borhani AA
Eur Radiol; 2021 Jan; 31(1):256-263. PubMed ID: 32757050
[TBL] [Abstract][Full Text] [Related]
40. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
